⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11771912 | 1.00 | — | — | |
| SCHEMBL11076177 | 0.97 | — | — | |
| SCHEMBL11066162 | 0.91 | — | — | |
| SCHEMBL11772656 | 0.88 | — | — | |
| SCHEMBL11069382 | 0.88 | — | — | |
| SCHEMBL11075868 | 0.88 | — | — | |
| SCHEMBL11771921 | 0.88 | — | — | |
| SCHEMBL11778366 | 0.88 | — | — | |
| SCHEMBL11778362 | 0.88 | — | — | |
| SCHEMBL11075866 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024140638-A1 | COMPOUND BASED ON SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE-BASED ISOINDOLINONE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| JP-2000510153-A | — | — | 2000-08-08 | — | — | JP | claimed |
| EP-0906315-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | claimed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | claimed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| CN-122010929-A | Lactam structure CDK inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024140638-A1 | COMPOUND BASED ON SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE-BASED ISOINDOLINONE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-6986981-B2 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050153244-A1 | Sulfonate derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORP. | 2005-07-14 | — | — | US | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| US-20040002007-A1 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORP. | 2004-01-01 | — | — | US | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| EP-0906315-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |